A New Study Published in The Annals of Thoracic Surgery: Daxor’s BVA-100 Device Reveals Unexpected Blood Loss of 38% in Car...
April 19 2018 - 9:00AM
Daxor Corporation
(NYSE MKT: DXR), an investment
company with medical instrumentation and biotechnology operations,
announces the publication of new research utilizing the BVA-100
blood volume analyzer that highlights significant, often
unrecognized blood loss in cardiac surgery. The paper entitled
“Measurement of Blood Loss in Cardiac Surgery: Still Too Much”
appears in the April issue of The Annals of Thoracic Surgery.
Study author Mark Nelson, MD of Virginia
Commonwealth University stated that the surprising results of his
study showed the inadequacy of current methods of evaluating blood
loss, including the widespread use of hematocrit and hemoglobin:
“Contrary to the long-held belief that red blood cells are largely
conserved during cardiac surgery they are in fact reduced by 38%.“
He added, “This data beckons the question of transfusion, should
peripheral hematocrit continue to be utilized as a
determinant.”
Michael Feldschuh CEO of Daxor stated, “This
study highlights the BVA-100’s unique ability to illuminate
intravascular fluid derangements that are missed by standard
diagnostic tests. With over 500,000 coronary bypass surgeries,
3,200 transplants, and hundreds of thousands of other cardiac and
non-cardiac surgeries performed annually in the United State, the
need for optimal care and accurate measurement of surgical blood
loss is acute. We see this as a very large and significant
additional market for our product and look forward to subsequent
research studies planned in this area.”
Surgical and non-surgical anemia caused by blood
loss is a common ailment that poses significant risk to patients.
Standard tests for determining blood loss or anemia lack the
specificity and sensitivity of the BVA-100 test, which precisely
quantifies whole blood and red blood cell volume with 98%
accuracy.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Daxor Corporation: Soren Thompson 212-330-8502 (Investor Relations) sthompson@daxor.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Sep 2023 to Sep 2024